Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.

Blood Adv · 2023 · PMC10539870 · PMID 36763537

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = .09so close (0.05 < p ≤ 0.1)

Though there was a nominal difference in median PFS for the KPd cohort at 17 vs 10 months for standard-risk vs high-risk disease, respectively, it did not reach statistical significance (hazard ratio 0.62; 95% CI, 0.35-1.09; P = .09) ( supplemental Figure 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.